Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

Completed

• Conditions: Cancer

• Registration Number: NCT01370980
• Lead Sponsor: Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Brief Summary

The purpose of this study is to implement a support interdisciplinary program(oncologists, pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral oncology treatments. The aim is to ensure continuity of care between professionals,effectiveness of treatment and patient safety.

Detailed Description

80 patients will be included in swiss-romande hospitals and private oncologists and followed by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration is 48 weeks, with a motivational interviewing at least every three months. Patient adherence will be assessed electronically by MEMS (Medication Event Monitoring System).

Study Timeline

• Study Start: 2010-07
• Study First Submitted: 2011-06-03
• Study First Submitted QC: 2011-06-09
• Study First Posted: 2011-06-10
• Primary Completion: 2011-12
• Study Completion: 2014-09
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-21
• Last Update Posted: 2022-11-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 43

Inclusion Criteria

• 18 years and older
• Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib, nilotinib, everolimus, deferasirox)
• French speaking

Exclusion Criteria

• None

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in Medication adherence	3 months, 6 months, 9 months, 12 months	MEMS data, completed by informations given in motivational interviewing

Secondary Outcome Measures

Name	Time	Method
Program implementation	1 year	Evaluating the implementation of the program in pharmacies
Effect of Adverse Drug Reaction (ADR) on medication adherence	1 year	By MEMS data and motivational interviewing informations
Oncologists, nurses, pharmacists and patients satisfaction	1 year	By questionnaire and interviews
Change in Adverse Drug Reaction (ADR)	3 months, 6 months, 9 months, 12 months	To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.

Trial Locations

Locations (1)

Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV; 🇨🇭 Lausanne, Vaud, Switzerland